In his latest research, @[Joaquin F. Mould, PhD], analyzed the impact of low influenza vaccination rates on U.S. hospital resources. Study findings predicted that increasing vaccination rates to 45% or more can reduce the impact of influenza and improve health outcomes. Watch the full video to learn more about the study and why boosting #vaccination rates is critical. #publichealth #influenza #DrivenByOurPromise
CSL's 2024 Annual General Meeting (AGM)
CSL's 2024 AGM was held on Tuesday, 29th October 2024 (AEDT).
Full Information and Webcast Recording available.
We have released our 2024 Annual Report Click here to read the Annual Report → | We have announced our 2024 Full Year Financial Results for the period ending June 30th 2024. Click here to view Information and Webcast Recording →
CSL. Always Evolving for a Better World.
CSL has delivered biotechnology excellence for over a century. Today, with the combined expertise of CSL Behring, CSL Plasma, CSL Seqirus and CSL Vifor, CSL’s offerings are more diverse than ever to help ensure patients and people everywhere get the treatments they need. We’re always improving so life can, too.
Our Businesses and ProductsCSL. Always Evolving for a Better World.
CSL has delivered biotechnology excellence for over a century. Today, with the combined expertise of CSL Behring, CSL Plasma, CSL Seqirus and CSL Vifor, CSL’s offerings are more diverse than ever to help ensure patients and people everywhere get the treatments they need. We’re always improving so life can, too.
Our Businesses and ProductsCSL Behring. Leading the Way in Treating Rare and Serious Diseases.
CSL Behring is a global biotech leader with a broad range of biotherapies for rare and serious diseases including bleeding disorders, immunodeficiencies, hereditary angioedema, neurological disorders and Alpha 1 Antitrypsin Deficiency.
More About CSL BehringCSL Seqirus. Global Vaccine Leader.
Through the power of innovation, our vision is to advance science to enhance public health worldwide. We stand on the front line with partners in public health discovering, developing, and delivering pioneering vaccine solutions to safeguard people and communities across the world.
More About CSL SeqirusCSL Vifor. Changing the Game in Iron Deficiency and Nephrology.
The newest member of the CSL family, CSL Vifor is a global leader in iron deficiency and nephrology and is committed to launching the next generation of therapies to truly address the full spectrum of kidney disease, with a focus on dialysis and rare disease.
More About CSL ViforVita: Original Stories
'Vita' means life. It's also where we share the stories of biotech's promise to patients and public health.
Careers at CSL
We are committed to helping employees fulfill their career aspirations while working in a values-based culture. Are you next?
Pictured: CSL employees in Melbourne, Australia